Todos Medical Receives Notice of Allowance from th
Post# of 30067
(Total Views: 572)
Posted On: 05/01/2019 8:19:29 AM
Todos Medical Receives Notice of Allowance from the USPTO Covering the Early Diagnosis of Lung Cancer Using the Todos Biochemical Infrared Analysis (TBIA)
May 1, 2019 at 8:00 AM EDT
REHOVOT, Israel and NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced it has received a Notice of Allowance from the United States Patent & Trademark Office (USPTO) covering the use of its’ proprietary TBIA (Todos Biochemical Infrared Analysis) to detect the presence of a solid tumor in the lung. The approved claims cover the use of isolating, drying and measuring an infrared (IR) spectrum of dried blood plasma to identify the presence of a cancerous tumor in the lung.
“There is a significant unmet medical need for the early detection of lung cancer, for which there are currently no diagnostic tests approved. Receiving this Notice of Allowance is a very positive development for Todos Medical as it further demonstrates the capabilities of our proprietary technology’s novel approach to screen for cancers in the blood from different tissues of origins,” said Dr. Herman Weiss, President & CEO of Todos. “Developing a screening blood test to detect lung cancer at an early stage would be tremendously beneficial to millions of patients, the medical community and the general population. The company is currently commercializing its breast cancer screen in Europe and Israel via partnerships, is continuing to develop a screen for colon cancer for which we have received a CE Mark, and will evaluate next steps with our lung cancer testing technology based on our newly improved patent position”.
http://investor.todosmedical.com/news-release...ring-early
Aloha
May 1, 2019 at 8:00 AM EDT
REHOVOT, Israel and NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced it has received a Notice of Allowance from the United States Patent & Trademark Office (USPTO) covering the use of its’ proprietary TBIA (Todos Biochemical Infrared Analysis) to detect the presence of a solid tumor in the lung. The approved claims cover the use of isolating, drying and measuring an infrared (IR) spectrum of dried blood plasma to identify the presence of a cancerous tumor in the lung.
“There is a significant unmet medical need for the early detection of lung cancer, for which there are currently no diagnostic tests approved. Receiving this Notice of Allowance is a very positive development for Todos Medical as it further demonstrates the capabilities of our proprietary technology’s novel approach to screen for cancers in the blood from different tissues of origins,” said Dr. Herman Weiss, President & CEO of Todos. “Developing a screening blood test to detect lung cancer at an early stage would be tremendously beneficial to millions of patients, the medical community and the general population. The company is currently commercializing its breast cancer screen in Europe and Israel via partnerships, is continuing to develop a screen for colon cancer for which we have received a CE Mark, and will evaluate next steps with our lung cancer testing technology based on our newly improved patent position”.
http://investor.todosmedical.com/news-release...ring-early
Aloha
(1)
(0)